"Hispanics and individuals of African ancestry have been significantly underrepresented in research of Alzheimer’s disease, although engaging underserved minorities is critical..." says Dr. Reitz
Dr. Manly was elected to NAM for her pioneering work improving detection of cognitive impairment among racially, culturally, and socio-economically diverse adults
On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.